Accuray Inks $8M RaySearch Deal to Accelerate Online Adaptive Radiation Therapy
ARAY sits 16% above its 52-week low of $0.22.
Summary
Accuray and RaySearch Laboratories announced a definitive collaboration agreement to integrate RayStation treatment planning software with Accuray's Radixact and CyberKnife platforms, targeting online adaptive radiation therapy. Accuray will purchase specified RayStation licenses totaling $8 million, with revenue recognized primarily in Q3 and Q4 2026. The partnership aims to combine Accuray's photon-based delivery systems with RaySearch's planning and workflow software to enable real-time plan adjustments before treatment. This follows a period of financial distress for Accuray, including a $49.2M net loss, adverse auditor opinion, and liquidity covenant breach disclosed in the FY2026 10-K. The collaboration provides a strategic growth avenue and potential competitive differentiation in the adaptive therapy market, though the $8 million order is modest relative to Accuray's $100.9M quarterly revenue. Watch for regulatory clearances in some markets and the commercial rollout timeline.
At the time of this announcement, ARAY was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.6M. The 52-week trading range was $0.22 to $2.10. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: MFN by Modular Finance.